RXRX Recursion Pharmaceuticals, Inc.
Healthcare$2.97-1.33%ClosedMarket Cap: $1.33B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.55
P/S
20.31
EV/EBITDA
-1.57
DCF Value
$-9.02
FCF Yield
-24.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-34.4%
Operating Margin
-882.9%
Net Margin
-844.5%
ROE
-54.3%
ROA
-41.8%
ROIC
-47.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $6.5M | -93.0% | $-128.5M | $-117.5M | $— | — |
| Q4 null | $35.5M | 24.4% | $-108.3M | $-108.1M | $— | — |
| FY null | $74.7M | -62.0% | $-648.1M | $-644.8M | $— | — |
| Q3 null | $5.2M | -471.8% | $-172.2M | $-162.3M | $— | — |
| Q2 null | $19.1M | -5.5% | $-176.2M | $-171.9M | $— | — |
| Q1 null | $14.7M | -48.0% | $-191.4M | $-202.5M | $— | — |
| Q4 null | $4.5M | -183.6% | $-183.8M | $-178.9M | $— | — |
| FY null | $58.8M | 23.1% | $-479.0M | $-463.7M | $— | — |
| Q3 null | $26.1M | 53.7% | $-98.4M | $-95.7M | $— | — |
| Q2 null | $14.4M | 36.1% | $-100.5M | $-97.5M | $— | — |
| Q1 null | $13.5M | 17.2% | $-96.3M | $-91.4M | $— | — |
| Q4 2023 | $10.6M | 7.0% | $-98.9M | $-93.0M | $-0.40 | — |